These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 19614793)

  • 1. Change in hemoglobin A(1c) and C-reactive protein levels in patients with diabetes mellitus.
    Khatana SA; Taveira TH; Choudhary G; Eaton CB; Wu WC
    J Cardiometab Syndr; 2009; 4(2):76-80. PubMed ID: 19614793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Multifactorial Treatment Targets and Relative Importance of Hemoglobin A1c, Blood Pressure, and Low-Density Lipoprotein-Cholesterol on Cardiovascular Diseases in Chinese Primary Care Patients With Type 2 Diabetes Mellitus: A Population-Based Retrospective Cohort Study.
    Wan EYF; Fung CSC; Yu EYT; Chin WY; Fong DYT; Chan AKC; Lam CLK
    J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study.
    Simó R; Guerci B; Schernthaner G; Gallwitz B; Rosas-Guzmàn J; Dotta F; Festa A; Zhou M; Kiljański J
    Cardiovasc Diabetol; 2015 Sep; 14():116. PubMed ID: 26338040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies.
    Meier M; Hummel M
    Vasc Health Risk Manag; 2009; 5():859-71. PubMed ID: 19898642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple risk factor intervention and progression of coronary atherosclerosis in patients with type 2 diabetes mellitus.
    Kataoka Y; Shao M; Wolski K; Uno K; Puri R; Tuzcu EM; Nissen SE; Nicholls SJ
    Eur J Prev Cardiol; 2013 Apr; 20(2):209-17. PubMed ID: 22345692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical clinics versus usual care for patients with both diabetes and hypertension: a randomized trial.
    Edelman D; Fredrickson SK; Melnyk SD; Coffman CJ; Jeffreys AS; Datta S; Jackson GL; Harris AC; Hamilton NS; Stewart H; Stein J; Weinberger M
    Ann Intern Med; 2010 Jun; 152(11):689-96. PubMed ID: 20513826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of improved fitness beyond weight loss on cardiovascular risk factors in individuals with type 2 diabetes in the Look AHEAD study.
    Gibbs BB; Brancati FL; Chen H; Coday M; Jakicic JM; Lewis CE; Stewart KJ; Clark JM;
    Eur J Prev Cardiol; 2014 May; 21(5):608-17. PubMed ID: 23012688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Control of glycemia and other cardiovascular disease risk factors in older adults with type 2 diabetes mellitus: data from the Adult Diabetes Control and Management.
    Sazlina SG; Mastura I; Ahmad Z; Cheong AT; Adam BM; Jamaiyah H; Lee PY; Syed-Alwi SA; Chew BH; Sriwahyu T
    Geriatr Gerontol Int; 2014 Jan; 14(1):130-7. PubMed ID: 23581598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study.
    Mattoo V; Eckland D; Widel M; Duran S; Fajardo C; Strand J; Knight D; Grossman L; Oakley D; Tan M;
    Clin Ther; 2005 May; 27(5):554-67. PubMed ID: 15978304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks.
    Bergenstal RM; Li Y; Porter TK; Weaver C; Han J
    Diabetes Obes Metab; 2013 Mar; 15(3):264-71. PubMed ID: 23078638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of intensive multitherapy for patients with type 2 diabetes mellitus: a randomized controlled trial.
    Ménard J; Payette H; Baillargeon JP; Maheux P; Lepage S; Tessier D; Ardilouze JL
    CMAJ; 2005 Dec; 173(12):1457-66. PubMed ID: 16293781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy.
    Yu D; Murdoch SJ; Parikh SJ; Marcovina SM; Cobitz A; Chen H; Brunzell JD
    Diab Vasc Dis Res; 2006 Dec; 3(3):189-96. PubMed ID: 17160915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial.
    ; Wing RR
    Arch Intern Med; 2010 Sep; 170(17):1566-75. PubMed ID: 20876408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repeat measurements of glycated haemoglobin A(1c) and N-terminal pro-B-type natriuretic peptide: divergent behaviour in diabetes mellitus.
    Neuhold S; Resl M; Huelsmann M; Strunk G; Adlbrecht C; Rath C; Prager R; Luger A; Clodi M; Pacher R
    Eur J Clin Invest; 2011 Dec; 41(12):1292-8. PubMed ID: 21615391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of a low-glycemic index or a high-cereal fiber diet on type 2 diabetes: a randomized trial.
    Jenkins DJ; Kendall CW; McKeown-Eyssen G; Josse RG; Silverberg J; Booth GL; Vidgen E; Josse AR; Nguyen TH; Corrigan S; Banach MS; Ares S; Mitchell S; Emam A; Augustin LS; Parker TL; Leiter LA
    JAMA; 2008 Dec; 300(23):2742-53. PubMed ID: 19088352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous control of diabetes mellitus, hypertension, and hyperlipidemia in 2 health systems.
    Schroeder EB; Hanratty R; Beaty BL; Bayliss EA; Havranek EP; Steiner JF
    Circ Cardiovasc Qual Outcomes; 2012 Sep; 5(5):645-53. PubMed ID: 22851534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus.
    Fischer LT; Hochfellner DA; Knoll L; Pöttler T; Mader JK; Aberer F
    Cardiovasc Diabetol; 2021 Apr; 20(1):89. PubMed ID: 33894772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sex-specific differences in glycemic control and cardiovascular risk factors in older patients with insulin-treated type 2 diabetes mellitus.
    Göbl CS; Brannath W; Bozkurt L; Handisurya A; Anderwald C; Luger A; Krebs M; Kautzky-Willer A; Bischof MG
    Gend Med; 2010 Dec; 7(6):593-9. PubMed ID: 21195359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabetes: glycated hemoglobin is a marker of diabetes and CVD risk.
    Wareham NJ; Pfister R
    Nat Rev Cardiol; 2010 Jul; 7(7):367-8. PubMed ID: 20577298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline and 1-year interim follow-up assessment of Japanese patients initiating insulin therapy who were enrolled in the cardiovascular risk evaluation in people with type 2 diabetes on insulin therapy study: an international, multicenter, observational study.
    Kawamori R; Node K; Hanafusa T; Atsumi Y; Naito Y; Oka Y
    Cardiovasc Diabetol; 2013 Sep; 12():131. PubMed ID: 24011395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.